A Study of Secukinumab for the Treatment of Alopecia Areata
Last Updated:
05/05/2016
Status:
Completed
Country:
United States
Eligibility:
Age 18+; patch type alopecia areata
Drug:
Secukinumab
Administration:
Injection
Sponsor:
Icahn School of Medicine at Mount Sinai
Link:
Ichan School of Medicine at Mount Sinai is seeking volunteers for a study evaluating the effectiveness of a new study drug in the treatment of moderate to severe alopecia areata. The purpose of this study is to assess the effects of a new treatment called secukinumab in patients with alopecia areata.
Ichan School of Medicine at Mount Sinai
New York, New York
Phone: 212-241-3288
Click here for more information.